TrialDrug design, development and therapy2025
Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study.
Wenwei Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.